| Literature DB >> 27459375 |
Kirsti Krohn Garnæs1, Siv Mørkved2,3, Øyvind Salvesen2, Trine Moholdt1,4.
Abstract
BACKGROUND: The effectiveness of exercise training for preventing excessive gestational weight gain (GWG) and gestational diabetes mellitus (GDM) is still uncertain. As maternal obesity is associated with both GWG and GDM, there is a special need to assess whether prenatal exercise training programs provided to obese women reduce the risk of adverse pregnancy outcomes. Our primary aim was to assess whether regular supervised exercise training in pregnancy could reduce GWG in women with prepregnancy overweight/obesity. Secondary aims were to examine the effects of exercise in pregnancy on 30 outcomes including GDM incidence, blood pressure, blood measurements, skinfold thickness, and body composition. METHODS ANDEntities:
Mesh:
Year: 2016 PMID: 27459375 PMCID: PMC4961392 DOI: 10.1371/journal.pmed.1002079
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Fig 1Flow chart of the ETIP study.
Baseline characteristics of all women included in the ETIP study.
| Baseline Characteristic | Exercise Group ( | Control Group ( |
|---|---|---|
|
| 31.3 ± 3.8 | 31.4 ± 4.7 |
|
| 95.3 ± 12.8 | 98.3 ± 14.2 |
|
| 167.6 ± 5.9 | 167.1 ± 6.5 |
|
| 33.9 ± 3.8 | 35.1 ± 4.6 |
|
| ||
| Overweight, BMI 28.0–29.9 kg/m2 | 3 (6.6%) | 5 (11.1%) |
| Class 1 obesity, BMI 30.0–34.9 kg/m2 | 28 (62.2%) | 19 (42.2%) |
| Class 2 obesity, BMI 35.0–39.9 kg/m2 | 11 (24.4%) | 15 (33.3%) |
| Class 3 obesity, BMI ≥ 40.0 kg/m2 | 3 (6.6%) | 6 (13.3%) |
|
| ||
| 0 | 22 (47.8%) | 19 (42.2%) |
| 1 | 19 (41.3%) | 19 (42.2%) |
| 2 | 5 (10.9%) | 4 (8.9%) |
| ≥3 | 0 (0.0%) | 3 (6.7%) |
|
| 2 (4.7%) | 4 (8.9%) |
|
| ||
| Primary/secondary school | 1 (2.3%) | 3 (7.0%) |
| High school | 15 (34.1%) | 12 (27.9%) |
| University ≤4 y | 14 (31.8%) | 11 (25.6%) |
| University >4 y | 14 (31.8%) | 17 (39.5%) |
|
| 38 (82.6%) | 33 (73.3%) |
|
| ||
| WHO 2009 definition | ||
| 4 (8.7%) | 4 (8.7%) | 4 (8.9%) |
| WHO/IADPSG 2013 definition | ||
| 8 (18.2%) | 8 (18.2%) | 13 (29.5%) |
|
| 3 (7.0%) | 4 (9.5%) |
|
| ||
| Fat mass (kg) | 40.0 ± 7.7 | 44.1 ± 10.3 |
| Fat mass (percent) | 43.1 ± 3.8 | 44.8 ± 5.5 |
| Fat-free mass (kg) | 52.4 ± 5.6 | 53.3 ± 6.1 |
| Fat-free mass (percent) | 56.9 ± 3.8 | 55.2 ± 5.5 |
|
| ||
| Biceps area (mm) | 20.3 ± 8.9 | 22.3 ± 8.8 |
| Triceps area (mm) | 28.8 ± 7.0 | 31.2 ± 7.2 |
| Subscapular area (mm) | 30.5 ± 8.6 | 33.1 ± 7.9 |
|
| ||
| Systolic blood pressure (mm Hg) | 126.3 ± 20.9 | 127.9 ± 12.9 |
| Diastolic blood pressure (mm Hg) | 75.0 ± 10.0 | 78.0 ± 8.4 |
|
| ||
| Fasting glucose (mmol/l) | 4.6 ± 0.4 | 5.0 ± 0.8 |
| 120-min glucose (mmol/l) | 6.2 ± 1.1 | 6.1 ± 1.6 |
| Insulin (pmol/l) | 158.3 ± 62.5 | 150.0 ± 70.8 |
| HbA1c (percent) | 5.2 ± 0.3 | 5.4 ± 0.4 |
| Insulin C-peptide (nmol/l) | 0.7 ± 0.7 | 0.7 ± 0.4 |
| Triglycerides (mmol/l) | 1.4 ± 0.4 | 1.5 ± 0.2 |
| Ferritin (pmol/l) | 147.4 ± 97.5 | 84.9 ± 49.4 |
| HDL cholesterol (mmol/l) | 1.6 ± 0.3 | 1.8 ± 0.3 |
| LDL cholesterol (mmol/l) | 3.0 ± 0.9 | 3.0 ± 0.5 |
| Total cholesterol (mmol/l) | 5.0 ± 1.3 | 5.1 ± 1.2 |
| Hemoglobin (g/l) | 127.0 ± 100.0 | 126 ± 8.0 |
| High-sensitivity CRP (mg/l) | 8.4 ± 3.5 | 10.2 ± 5.0 |
| HOMA2-IR | 2.6 ± 1.2 | 2.5 ± 1.2 |
Observed data are presented as mean ± standard deviation or number of participants (percent). Missing: number of participants with missing data in each group is 0 to 3 for all variables except for body composition, where 14 are missing in the exercise group and 12 in the control group.
*Fasting plasma glucose ≥ 7.0 mmol/l or 120-min plasma glucose ≥ 7.8 mmol/l.
**Fasting plasma glucose ≥ 5.1 mmol/l or 120-min plasma glucose ≥ 8.5 mmol/l.
***Body composition was measured by air displacement plethysmography (BOD POD).
Primary and secondary outcomes in late pregnancy and at delivery.
| Outcome at Late Pregnancy/Delivery | Baseline Mean | Exercise Group ( | Control Group ( | Between-Group Comparison | ||||
|---|---|---|---|---|---|---|---|---|
| Final Mean | 95% CI | Final Mean | 95% CI | Mean Difference | 95% CI |
| ||
|
| 10.5 | 8.9, 12.0 | 9.2 | 6.8, 11.6 | 1.29 | −1.58, 4.05 | 0.35 | |
|
| 96.8 | 107.1 | 103.9, 110.3 | 106.1 | 102.9, 109.3 | 0.92 | −1.35, 3.18 | 0.43 |
|
| 34.5 | 37.4 | 36.4, 38.4 | 37.0 | 36.1, 38.0 | 0.35 | −0.45, 1.15 | 0.85 |
|
| ||||||||
| Fat mass (kg) | 42.2 | 46.4 | 43.8, 49.0 | 45.0 | 42.4, 47.7 | 1.35 | −0.98, 3.68 | 0.26 |
| Fat mass (%) | 44.0 | 43.7 | 42.5, 45.0 | 43.3 | 42.0, 44.6 | 0.43 | −0.67, 1.52 | 0.45 |
| Fat-free mass (kg) | 53.0 | 57.7 | 56.0, 59.4 | 58.3 | 56.6, 60.0 | −0.59 | −2.28, 1.11 | 0.50 |
| Fat-free mass (%) | 55.8 | 56.5 | 55.2, 57.8 | 56.5 | 55.2, 57.8 | −0.05 | −1.17, 1.07 | 0.93 |
|
| ||||||||
| Biceps area (mm) | 21.3 | 18.5 | 16.2, 20.8 | 18.3 | 15.9, 20.6 | 0.23 | −2.42, 2.89 | 0.86 |
| Triceps area (mm) | 30.0 | 28.0 | 26.1, 29.8 | 29.8 | 28.0, 31.6 | −1.82 | −3.82, 0.17 | 0.07 |
| Subscapular area (mm) | 31.8 | 30.8 | 28.6, 33.0 | 31.0 | 28.8−33.2 | −0.26 | −2.63, 2.12 | 0.83 |
|
| ||||||||
| Systolic BP (mm Hg) | 124.5 | 120.4 | 116.4, 124.3 | 128.1 | 124.0, 132.2 | −7.73 | −13.23, −2.22 | 0.006 |
| Diastolic BP (mm Hg) | 76.0 | 76.6 | 73.8, 79.3 | 80.2 | 77.3, 83.0 | −3.61 | −7.42, 0.20 | 0.06 |
|
| ||||||||
| Fasting glucose (mmol/l) | 4.7 | 4.6 | 4.4, 4.8 | 4.5 | 4.3, 4.7 | 0.09 | −0.20, 0.37 | 0.56 |
| 120-min glucose (mmol/l) | 6.0 | 6.2 | 5.6, 6.7 | 5.8 | 5.3, 6.4 | 0.33 | −0.44, 1.10 | 0.40 |
| Insulin (pmol/l) | 142.4 | 209.0 | 179.9, 238.2 | 208.4 | 177.1, 238.9 | 0.9 | −39.4, 41.1 | 0.97 |
| HbA1c (%) | 5.2 | 5.4 | 5.3, 5.5 | 5.4 | 5.3, 5.5 | −0.06 | −0.20, 0.08 | 0.41 |
| Insulin C-peptide (nmol/l) | 0.6 | 0.7 | 0.6, 0.9 | 0.8 | 0.7, 1.0 | −0.10 | −0.31, 0.11 | 0.37 |
| Triglycerides (mmol/l) | 1.4 | 2.6 | 2.3, 2.9 | 2.4 | 2.0, 2.7 | −0.25 | −0.77, 0.13 | 0.24 |
| Ferritin (pmol/l) | 127.0 | 29.7 | 7.0, 52.4 | 37.7 | 14.8, 60.9 | −8.20 | −40.18, 23.64 | 0.62 |
| HDL cholesterol (mmol/l) | 1.7 | 1.6 | 1.5, 1.7 | 1.7 | 1.6, 1.8 | −0.08 | −0.22, 0.06 | 0.27 |
| LDL cholesterol (mmol/l) | 2.8 | 3.6 | 3.3, 3.8 | 3.6 | 3.4, 3.9 | −0.06 | −0.43, 0.30 | 0.73 |
| Total cholesterol (mmol/l) | 5.0 | 6.1 | 5.8, 6.5 | 6.4 | 6.0, 6.8 | −0.28 | −0.81, 0.25 | 0.30 |
| Hemoglobin (g/l) | 127.0 | 118.0 | 115.0, 120.0 | 117.0 | 114.0, 120.0 | 1.1 | −2.9, 5.1 | 0.59 |
| High-sensitivity CRP (mg/l) | 10.7 | 6.6 | 4.4, 8.8 | 6.5 | 4.3, 8.7 | 0.09 | −3.01, 3.18 | 0.96 |
| HOMA2-IR | 2.5 | 3.6 | 3.2, 4.1 | 3.7 | 3.2, 4.2 | −0.04 | −0.68, 0.59 | 0.90 |
Intention-to-treat model-based analyses with baseline mean (all participants), mean and 95% CI at late pregnancy/delivery for the exercise group and the control group, and comparison between groups presented as mean difference, 95% CI, and p-value. The mother’s weight was measured and BMI calculated at delivery, the rest of the measurements were at gestational week 34–37. The number of participants with missing data in the exercise group varied between 0 and 5, in the control group between 0 and 3, for all variables except for body composition, where 12 participants in each group had missing data. The effect of treatment was assessed with linear mixed models. For the primary and secondary outcomes, the effect of time and treatment was taken as a fixed effect. Due to randomization, there were no systematic differences between groups at baseline. To account for repeated measurements, participant ID was included as a random effect.
*Body composition was measured by air displacement plethysmography (BOD POD).
BP, blood pressure.
Secondary outcomes in late pregnancy and at delivery.
| Outcome at Late Pregnancy/Delivery | Exercise Group ( | Control Group ( | Between-Group Comparison | ||
|---|---|---|---|---|---|
| Odds Ratio | 95% CI |
| |||
|
| |||||
| WHO 2009 definition | 2 (6.1) | 9 (27.3) | 0.1 | 0.016, 0.949 | 0.04 |
| WHO/IADPSG 2013 definition | 5 (14.7) | 8 (24.2) | 0.5 | 0.126, 2.349 | 0.42 |
|
| 3 (9.1) | 7 (22.6) | 0.2 | 0.019, 1.976 | 0.17 |
|
| 21 (58.3) | 16 (44.4) | 0.6 | 0.225, 1.453 | 0.35 |
Intention-to-treat analysis based on observed data for the exercise and the control group and comparison between groups are presented as number of participants (percentage), odds ratio, 95% CI, and p-value. The analyses of GDM and hypertension were done on the basis of blood tests and blood pressure measurements in late pregnancy. The analysis of GWG relative to IOM recommendations was done on the basis of weight measurements at delivery. The number of participants with missing data in the exercise group varied between 0 and 5, in the control group between 0 and 3. Data were analyzed by a mixed logistic regression model.
*Fasting plasma glucose ≥ 7.0 mmol/l or 120-min plasma glucose ≥ 7.8 mmol/l.
**Fasting plasma glucose ≥ 5.1 mmol/l or 120-min plasma glucose ≥ 8.5 mmol/l.
Abortions, premature deliveries, and other adverse events occurring during follow-up.
| Adverse Event | Exercise Group ( | Control Group ( |
|---|---|---|
| Abortion before gestational week 22 | 3 (6.5%) | 3 (6.7%) |
| Delivery before gestational week 37 | 1 (2.2%) | 1 (2.2%) |
| Other adverse events | 0 | 0 |
Data are presented as number (percent).